Security
CALCIMEDICA INC Common Stock · CALC
CALCOTCCommon stockHistorical · closed Jun 14, 2023CIK 1534133Updated Oct 19, 2026
Name history
CalciMedica, Inc. /DE/ · through Mar 22, 2023GRAYBUG VISION, INC. · through Mar 15, 2023GRAYBUG, Inc. · through May 13, 2016GRAYBUG LLC · through Oct 7, 2014
Current security for this SEC filerCALC · NASDAQ
CALC price & chart
Historical security
This listing closed Jun 14, 2023. Live provider charts are shown only for current listings.
Current security: CALC
About the company
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company's pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora™, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary arterial hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PAH and a planned Phase 2b trial in acute pancreatitis. CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit www.calcimedica.com.
In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
Other Events
Items 8.01, 9.01
424B5 filing
4 filing
Show 5 more recent filings
S-8 filing
Other Events
Items 8.01
Other Events
Items 8.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 14,913,000Source | 16,212,000Source | 19,503,000Source | 19,080,000Source | 21,052,000Source | 8,609,000Source | 25,347,000Source | 27,134,000Source | 13,591,000Source | 19,794,000Source | 12,185,000Source | 39,670,000Source |
| Property, Plant and Equipment, NetUSD | 49,000Source | 130,000Source | 36,000Source | 105,000Source | 138,000Source | 43,000Source | 118,000Source | 153,000Source | 50,000Source | 119,000Source | 167,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,470,000Source | 9,151,000Source | 18,617,000Source | 5,918,000Source | 5,056,000Source | 8,164,000Source | 12,556,000Source | 6,755,000Source | 11,520,000Source | 7,935,000Source | 5,530,000Source | 17,304,000Source |
| Assets, CurrentUSD | 14,853,000Source | 15,686,000Source | 19,463,000Source | 18,964,000Source | 20,442,000Source | 8,555,000Source | 25,218,000Source | 26,604,000Source | 13,530,000Source | 19,665,000Source | 11,605,000Source | 39,670,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 539,000Source | 1,083,000Source | 575,000Source | 655,000Source | 1,305,000Source | 122,000Source | 197,000Source | 894,000Source | 259,000Source | 248,000Source | 367,000Source | 542,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 15,181,000Source | 7,182,000Source | 13,990,000Source | 12,977,000Source | 7,214,000Source | 9,713,000Source | 14,459,000Source | 9,887,000Source | 20,232,000Source | 5,384,000Source | 4,028,000Source | 3,699,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 4,000Source | 3,000Source | 6,000Source | 4,000Source | 3,000Source | 4,000Source | 4,000Source | 3,000Source | 4,000Source | 4,000Source | 1,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -178,566,000Source | -155,506,000Source | -192,002,000Source | -170,762,000Source | -149,888,000Source | -184,350,000Source | -164,806,000Source | -145,934,000Source | -189,326,000Source | -159,764,000Source | -146,064,000Source | -204,793,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,000Source | 4,000Source | -1,000Source | -4,000Source | -9,000Source | — | -1,000Source | -17,000Source | 0Source | 4,000Source | 2,000Source | -37,000Source |
| Stockholders' Equity Attributable to ParentUSD | -268,000Source | 9,030,000Source | 5,513,000Source | 6,103,000Source | 13,838,000Source | -1,104,000Source | 10,888,000Source | 17,247,000Source | -6,641,000Source | 14,410,000Source | 8,157,000Source | 35,971,000Source |
| Additional Paid in Capital, Common StockUSD | 178,293,000Source | 164,529,000Source | 197,510,000Source | 176,865,000Source | 163,732,000Source | 183,242,000Source | 175,691,000Source | 163,195,000Source | 182,681,000Source | 174,166,000Source | 154,218,000Source | 240,799,000Source |
| Liabilities and EquityUSD | 14,913,000Source | 16,212,000Source | 19,503,000Source | 19,080,000Source | 21,052,000Source | 8,609,000Source | 25,347,000Source | 27,134,000Source | 13,591,000Source | 19,794,000Source | 12,185,000Source | 39,670,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,681,000Source | 3,782,000Source | 3,490,000Source | 3,477,000Source | 3,914,000Source | 5,313,000Source | 4,459,000Source | 4,287,000Source | 3,782,000Source | 3,684,000Source | 4,028,000Source | 3,699,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 203,000Source |
| Accounts Payable, CurrentUSD | 1,133,000Source | 1,536,000Source | 2,073,000Source | 1,912,000Source | 2,144,000Source | 1,675,000Source | 2,016,000Source | 1,535,000Source | 1,161,000Source | 1,998,000Source | 1,419,000Source | 1,716,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 200,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 14,100,000Source | 14,600,000Source | 18,600,000Source | 18,000,000Source | 19,100,000Source | 8,200,000Source | 24,600,000Source | 25,700,000Source | 13,000,000Source | 18,700,000Source | 11,200,000Source | — |
| Short-term InvestmentsUSD | 8,614,000Source | 5,452,000Source | 0Source | 12,039,000Source | 14,081,000Source | 0Source | 12,069,000Source | 18,955,000Source | 1,496,000Source | 10,734,000Source | 5,708,000Source | 21,824,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 4,976,000Source | -5,042,000Source | -29,562,000Source | -13,700,000Source | -34,357,000Source | -35,605,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 58,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 561,000Source | 549,000Source | 2,971,000Source | 2,313,000Source | 12,039,000Source | 6,713,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 514,000Source | -87,000Source | -840,000Source | 601,000Source | -1,427,000Source | 1,304,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,856,000Source | -4,878,000Source | -21,178,000Source | -21,146,000Source | -25,730,000Source | -22,879,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 1,500,000Source | -1,243,000Source | 9,551,000Source | -4,423,000Source | 8,884,000Source | 26,958,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 9,000Source | 28,000Source | 8,000Source | 78,000Source | 308,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | — | 139,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 10,742,000Source | 15,212,000Source | 27,974,000Source | 20,900,000Source | -139,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,356,000Source | 4,621,000Source | 3,585,000Source | 2,405,000Source | 4,054,000Source | 3,940,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 319,000Source | 0Source | 1,087,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 12,039,000Source | 6,713,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 14,100,000Source | 14,600,000Source | 18,600,000Source | 18,000,000Source | 8,200,000Source | 24,600,000Source | 13,000,000Source | 18,700,000Source | 11,200,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 7,000Source | 15,000Source | 46,000Source | 58,000Source | 58,000Source | 338,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | -97,000Source |
| General and Administrative ExpenseUSD | — | — | 1,767,000Source | 2,190,000Source | 1,910,000Source | 2,569,000Source | 2,126,000Source | 2,273,000Source | 7,887,000Source | 9,726,000Source | 22,216,000Source | 19,104,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 1,000Source | — |
| InterestExpenseNonoperatingUSD | — | — | 326,000Source | 0Source | 325,000Source | 324,000Source | 319,000Source | 447,000Source | 1,422,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 575,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,804,000Source | -5,618,000Source | -7,652,000Source | -5,956,000Source | 4,976,000Source | -5,042,000Source | -29,562,000Source | -13,700,000Source | -34,357,000Source | -35,605,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,804,000Source | -5,618,000Source | -7,652,000Source | -5,956,000Source | 4,976,000Source | -5,042,000Source | -29,562,000Source | -13,700,000Source | -34,357,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -2,186,000Source | 118,000Source | -3,640,000Source | 665,000Source | 10,587,000Source | 1,455,000Source | -6,441,000Source | 10,504,000Source | 3,718,000Source | — |
| Operating ExpensesUSD | — | — | 5,618,000Source | 5,736,000Source | 4,012,000Source | 6,621,000Source | 5,611,000Source | 6,497,000Source | 23,121,000Source | 24,204,000Source | 38,075,000Source | 36,180,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | — | 290,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | 231,000Source | 269,000Source | — | — | 268,000Source | 1,014,000Source | 660,000Source | — |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 0Source | 6,634,000Source | 15,916,000Source | 29,002,000Source | 6,118,000Source | 35,569,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 8,000Source | 8,000Source | 27,905,000Source | 10,340,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 25,000Source | 20,000Source | — | — |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 626,000Source | 781,000Source | 540,000Source | 1,174,000Source | 561,000Source | 549,000Source | 2,971,000Source | 2,313,000Source | 12,039,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 1,000Source | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -5,618,000Source | -5,736,000Source | -4,012,000Source | -6,621,000Source | -5,611,000Source | -6,497,000Source | -23,121,000Source | -24,204,000Source | -38,075,000Source | -36,180,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | 231,000Source | 269,000Source | — | — | 268,000Source | 1,014,000Source | 660,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -29,562,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 1,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,804,000Source | -5,618,000Source | -7,652,000Source | -5,956,000Source | 4,976,000Source | -5,042,000Source | -29,562,000Source | -13,700,000Source | -34,357,000Source | -35,605,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.52Source | -0.5Source | -0.45Source | -0.4Source | 0.31Source | -0.36Source | -1.97Source | -1.22Source | -7.66Source | -1.66Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.52Source | -0.5Source | -0.45Source | -0.4Source | 0.3Source | -0.36Source | -1.97Source | -1.22Source | -7.66Source | -1.66Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 15,076,456Source | 11,134,964Source | 17,100,457Source | 14,995,404Source | 15,822,163Source | 14,121,569Source | 15,011,321Source | 11,245,915Source | 4,486,258Source | 21,489,280Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 15,076,456Source | 11,134,964Source | 17,100,457Source | 14,995,404Source | 16,328,947Source | 14,121,569Source | 15,011,321Source | 11,245,915Source | 4,486,258Source | 21,489,280Source |
| Interest Expense (non-operating)USD | — | — | 326,000Source | 0Source | 325,000Source | 324,000Source | 319,000Source | 447,000Source | 1,422,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related CostsUSD | — | — | — | — | — | — | — | — | — | 10,500,000Source | 10,500,000Source | — |
| General and Administrative ExpenseUSD | — | — | 1,767,000Source | 2,190,000Source | 1,910,000Source | 2,569,000Source | 2,126,000Source | 2,273,000Source | 7,887,000Source | 9,726,000Source | 22,216,000Source | 19,104,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 575,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -7,804,000Source | -5,618,000Source | -7,652,000Source | -5,956,000Source | 4,976,000Source | -5,042,000Source | -29,562,000Source | -13,700,000Source | -34,357,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -2,186,000Source | 118,000Source | -3,640,000Source | 665,000Source | 10,587,000Source | 1,455,000Source | -6,441,000Source | 10,504,000Source | 3,718,000Source | — |
| Operating ExpensesUSD | — | — | 5,618,000Source | 5,736,000Source | 4,012,000Source | 6,621,000Source | 5,611,000Source | 6,497,000Source | 23,121,000Source | 24,204,000Source | 38,075,000Source | 36,180,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Research and Development ExpenseUSD | — | — | 3,851,000Source | 3,546,000Source | 2,102,000Source | 4,052,000Source | 3,485,000Source | 4,224,000Source | 15,234,000Source | 14,478,000Source | 15,859,000Source | 14,113,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 626,000Source | 781,000Source | 540,000Source | 1,174,000Source | 561,000Source | 549,000Source | 2,971,000Source | 2,313,000Source | 12,039,000Source | — |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
Offerings
Registration 333-297681
Registration 333-293972
Filing attachments
ck0001534133-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 ck0001534133-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the Phase 2b trial in acute pancreati…
Read attachment ↗d169379dex423.htm · S-3 · 2026-07-24
Exhibit 4.23 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION …
Read attachment ↗d169379dex424.htm · S-3 · 2026-07-24
Exhibit 4.24 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION …
Read attachment ↗d142943dex41.htm · 8-K · 2026-06-24
EX-4.1 2 d142943dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 Execution Version THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFE…
Read attachment ↗d142943dex42.htm · 8-K · 2026-06-24
EX-4.2 3 d142943dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIE…
Read attachment ↗d142943dex43.htm · 8-K · 2026-06-24
EX-4.3 4 d142943dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIE…
Read attachment ↗